Rigel Pharmaceuticals, Inc. (RIGL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2600-0.0600 (-1.81%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 3.3200 |
| Open | 3.3000 |
| Bid | 3.2600 x 4000 |
| Ask | 3.2900 x 4000 |
| Day's Range | 3.2200 - 3.3000 |
| 52 Week Range | 1.4500 - 5.5000 |
| Volume | 1,525,635 |
| Avg. Volume | 3,811,309 |
| Market Cap | 554.594M |
| Beta (5Y Monthly) | 1.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- Simply Wall St.
Need To Know: Analysts Are Much More Bullish On Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Revenues
Shareholders in Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) may be thrilled to learn that the analysts have just...
- Zacks
Rigel Pharmaceuticals (RIGL) Reports Q4 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- Motley Fool
3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (NYSE: LLY). A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often overlooked biotech stock. Here's why investors can look forward to outstanding returns from Rigel Pharmaceuticals in the years to come.
© 2021 Verizon Media. All rights reserved.
